Efficacy and Safety of Loxoprofen Sodium Hydrogel Patch in Patients with Chronic Inflammatory Pain: A 4-Week Real-World Study
Yang Chen,Xiaoen Bian,Junnan Wang,Fang Yan,Jing Gao,Tao Sun
DOI: https://doi.org/10.2147/jpr.s437462
IF: 2.8319
2024-02-06
Journal of Pain Research
Abstract:Yang Chen, Xiaoen Bian, Junnan Wang, Fang Yan, Jing Gao, Tao Sun Department of Pain Management, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China Correspondence: Tao Sun, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, Shandong, 250021, People's Republic of China, Email Purpose: Chronic inflammatory pain is usually treated with oral non-steroidal anti-inflammatory drugs (NSAIDs). However, oral NSAIDs can cause some adverse events, and local preparation is an important alternative drug. Currently, small sample clinical studies show that loxoprofen sodium hydrogel patch (LX-P) has good analgesic and anti-inflammatory effects; however, there is a lack of real-world clinical research data. Patients and Methods: This study included 60 patients with chronic inflammatory pain. They were treated with LX-P without affecting their real-world treatment for two weeks. Results: After 2 weeks of continuous medication, 93.33% of the patients stated that the treatment was effective. Only 3.33% of the patients had a relapse after 4 weeks. Moreover, the swelling range and degree of swelling decreased markedly and the dysfunction of the pain site was markedly alleviated. The total satisfaction of patients after treatment reached 90.00%. Conclusion: In this real-world observational study, LX-P showed good efficacy and safety in patients with chronic inflammatory pain. Keywords: loxoprofen sodium hydrogel patch, real-world study, chronic inflammatory pain, non-steroidal anti-inflammatory drugs Chronic inflammatory pain, such as pain resulting from osteoarthritis, frozen shoulder, cervical spondylosis, and myofasciitis, has a high incidence and recurrence rate. 1,2 Chronic inflammatory pain tends to have a low age of onset and significantly increases the medical and economic burden of patients, which can markedly reduce the quality of life without timely intervention. 3 According to the United Kingdom Health and Safety Executive, 5.7 million working days were lost between 2001 and 2002 due to low back pain, whereas 4.1 million working days were lost due to upper limb, neck, and shoulder pain, resulting in an annual economic loss of approximately £5.7 billion. 4 In China, the years of living with disability increased dramatically from 17.6 million to 28.1 million between 1990 and 2019. 5 Therefore, the treatment of chronic inflammatory pain is essential. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation associated with chronic diseases. 6,7 However, oral NSAIDs may increase the risk of cardiovascular and renal diseases and are known to interact with various medications, including antihypertensive agents, antithrombotic agents, antidepressants, and corticosteroids. 8,9 The use of oral non-selective NSAIDs [ie, cyclooxygenase (COX)-1 and COX-2 inhibitors] also increases the risk of upper gastrointestinal complications such as erosive gastritis and bleeding. 10 Topical NSAIDs have analgesic and anti-inflammatory effects similar to those of oral NSAIDs but with a potentially improved safety profile due to their reduced systemic absorption. 11 Therefore, the United States and European guidelines for osteoarthritis usually recommend topical NSAIDs rather than oral NSAIDs. 12,13 Loxoprofen (LX) is a non-selective NSAID prodrug that became the second most commonly used NSAID (after diclofenac) in China in 2007. 14 The LX in the loxoprofen sodium hydrogel patch (LX-P) penetrates directly into the affected area and relieves pain. 15 Currently, small-sample clinical studies have shown that LX-P has good analgesic and anti-inflammatory therapeutic effects; 7,15–17 however, there is a lack of data from real-world clinical studies. Real-world study (RWS) is a patient-centered outcome research that aims to evaluate the external validity and safety of intervention measures in real clinical settings. 18,19 Compared to RWS, randomized controlled trials have stricter inclusion criteria and intervention protocols, making it difficult to reflect the true clinical use of LX-P. This 4-week study aimed to evaluate the efficacy, safety, and patient compliance of topical LX-P in the treatment of chronic inflammatory pain in a real-world setting to provide a theoretical basis for future clinical treatment of patients with chronic inflammatory pain. Patients aged 18 years or older diagnosed with chronic inflammatory pain, including osteoarthritis, frozen shoulder, myofascial pain syndrome, tendinitis, tennis elbow, rheumatoid arthritis, gout, sacroiliac arthritis, an -Abstract Truncated-
clinical neurology